The Effect of Cyclosporine A on Dermal Fibroblast Cell - Transcriptomic Analysis of Inflammatory Response Pathway
- 22 October 2020
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 21 (12) , 1213-1223
Abstract
Background: The first immunosuppressive drug - cyclosporine A (CsA) has many unquestioned merits in maintaining organ transplants in patients, as well as, in the treatment of many inflammatory diseases, also associated with cutaneous manifestations. The main task of this drug is to suppress the inflammatory response at the sites of action, which is not well known. Objective: The objective of this study was to evaluate the influence of CsA in therapeutic concentration on the expression of genes associated with the inflammatory response pathway in normal human dermal fibroblasts (NHDF; CC-2511), and this study attempted to determine the mechanism of its action. Methods: The cytotoxicity MTT test was performed. The expression of the inflammatory response pathway genes was determined using HG-U133A_2.0 oligonucleotide microarrays. Statistical analysis was performed by GeneSpring 13.0 software using the PL-Grid platform. Results: Among the 5,300 mRNA, only 573 were changed significantly in response to CsA compared to the control fibroblasts (P≤0.05). CsA inhibited the expression of most genes associated with the inflammatory response in NHDFs. There were only 19 genes with a fold change (FC) lower than -2.0, among which EGR1, FOS, PBK, CDK1 and TOP2A had the lowest expression, as did CXCL2 which can directly impact inflammation. Furthermore, ZNF451 was strongly induced, and COL1A1, COL3A1, IL33, TNFRSFs were weakly up-regulated (FC lower than 2.0). Conclusion: The CsA in therapeutic concentration influences the genes linked to the inflammatory response (in the transcriptional level) in human dermal fibroblasts. The findings suggest that the potential mechanism of CsA action in this concentration and on these genes can be associated with a profibrotic and proapoptotic, and genotoxic effects.Keywords
Funding Information
- Medical University of Silesia (KNW-1-056/K/9/0 and KNW-1-057/K/8/0)
This publication has 63 references indexed in Scilit:
- hnRNP A1: The Swiss Army Knife of Gene ExpressionInternational Journal of Molecular Sciences, 2013
- Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalkJournal of Clinical Investigation, 2012
- Effects of interleukin-33 on cardiac fibroblast gene expression and activityCytokine, 2012
- Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial‐mesenchymal transition: Role of TGFβ signaling pathwayMolecular Carcinogenesis, 2011
- The use of cyclosporine in dermatology: Part IJournal of the American Academy of Dermatology, 2010
- Collagen-based cell migration models in vitro and in vivoSeminars in Cell & Developmental Biology, 2009
- GATA-6 is a novel transcriptional repressor of the human Tenascin-C gene expression in fibroblastsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2008
- Lipopolysaccharide induces CXCL2/macrophage inflammatory protein‐2 gene expression in enterocytes via NF‐κB activation: independence from endogenous TNF‐α and platelet‐activating factorImmunology, 2006
- Inflammation in epithelial skin tumours: Old stories and new ideasEuropean Journal of Cancer, 2006
- CYCLOSPORINE STIMULATES EXPRESSION OF TRANSFORMING GROWTH FACTOR-β IN RENAL CELLS POSSIBLE MECHANISM OF CYCLOSPORINES ANTIPROLIFERATIVE EFFECTSTransplantation, 1995